Avadel Pharma (AVDL) Tops Q2 EPS by 7c, Beats on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. TENB
7. CMG
8. KLAC
9. BIIB
10. ETSY

Go back to Avadel Pharma (AVDL) Tops Q2 EPS by 7c, Beats on Revenue

Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

August 7, 2025 7:00 AM EDT

-- Generated LUMRYZ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 --

-- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 --

-- Raises 2025 full year revenue guidance to $265 - $275 million --

-- Received Orphan Drug Designation from FDA for LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) --

        -- On track to complete enrollment in pivotal Phase 3... More